MARKET

CNSP

CNSP

CNS Pharmaceuticals
NASDAQ
2.310
-0.130
-5.33%
Opening 10:49 03/30 EDT
OPEN
2.580
PREV CLOSE
2.440
HIGH
2.580
LOW
2.240
VOLUME
9.00K
TURNOVER
--
52 WEEK HIGH
45.84
52 WEEK LOW
2.057
MARKET CAP
1.43M
P/E (TTM)
-0.0177
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CNSP last week (0323-0327)?
Weekly Report · 16h ago
Weekly Report: what happened at CNSP last week (0316-0320)?
Weekly Report · 03/23 10:23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 03/18 12:05
Weekly Report: what happened at CNSP last week (0309-0313)?
Weekly Report · 03/16 10:23
CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology
TipRanks · 03/11 13:02
CNS Pharmaceuticals launches new corporate growth strategy
TipRanks · 03/11 12:52
CNS Pharmaceuticals Launches Global Search For Neurology And Oncology Assets, Shifts Focus From Glioblastoma
Benzinga · 03/11 12:42
CNS Pharmaceuticals to Pursue Acquisition and In-Licensing of Neurology and Oncology Assets, While Exploring Out-Licensing of Berubicin and TPI 287 to Build a New Pipeline
Reuters · 03/11 12:35
More
About CNSP
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

Webull offers CNS Pharmaceuticals Inc stock information, including NASDAQ: CNSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNSP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNSP stock methods without spending real money on the virtual paper trading platform.